The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Gilenya Capsules, 0.5 mg of Novartis Pharmaceuticals Corporation (Novartis)
The first Phase III and second Phase III trials will be multi-centre, randomised, assessor-blind, active-comparator studies to determine the efficacy, safety and tolerability of orally administered Zintrodiazine
New appointments bring diagnostics and medtech expertise to strengthen healthcare delivery and policy engagement
New model focuses on continuity of care, combining therapy, routine and social engagement to support long-term recovery
The deal signals a clear push to expand access to care in underserved regions
VESCOP, ENTOD Pharmaceuticals, and APTI-MSB host the event to bridge lab-to-clinic gap in eye care
The agreements aim to strengthen medicine quality, patient safety and pharmaceutical research in India
As part of the partnership, Boehringer Ingelheim will provide access to its opnMe® platform, enabling broader scientific exchange and driving innovation-led research.
The summit brought together over 150 doctors, researchers, and practitioners worldwide
Multidisciplinary team expansion brings integrated medical, surgical, and radiation oncology services under one roof
Subscribe To Our Newsletter & Stay Updated
